scholarly journals The number, scope and geographic distribution of clinical researchers in Canada

2008 ◽  
Vol 31 (5) ◽  
pp. 222 ◽  
Author(s):  
Malathi Raghavan ◽  
J Dean Sandham
Keyword(s):  
Clinical Research ◽  
Geographic Distribution ◽  
Basic Research ◽  
Research Capacity ◽  
The United States ◽  
Research Grants ◽  
Principal Investigators ◽  
Randomized Controlled ◽  
Research Activities ◽  
The Ideal

Purpose: Despite international concerns about declining numbers of clinical researchers, the number of clinical researchers in Canada remains undocumented. Methods: The number and geographic distribution of clinical researchers in Canada and the scope of their research activities were estimated using, as an indicator, the data on clinical research projects funded by the Canadian Institutes for Health Research (CIHR). Results: Between fiscal years 1999-00 and 2006-07, 1,041 individual researchers—approximately 130 per year—were principal investigators (PIs) on clinical research grants. One hundred and 26 researchers received salary awards; 449 supervisors oversaw the clinical research activities of 230 fellows and 223 students with trainee awards. An additional 2,305 individuals served only as co-investigators on grants. Most (863 [83%]) PIs received funding for operating grants; 196 (19%) PIs received funding for randomized controlled trials. The institute of neurosciences, mental health and addiction funded the highest number of researchers (187 [18%] PIs, 40 [17%] fellows, and 73 [33%] students). Among provinces, Quebec led the nation with the highest number (45) of PIs per million population. Ontario had the highest number of clinical research fellows (10 per million population) while Quebec and Saskatchewan each hosted more students (11 per million). Conclusion: The number of Canadian investigators with funding for clinical research from CIHR was low. Although the ideal ratio of clinical to basic research capacity is not known, the possibility that the gap between laboratory-based research and clinical research is larger in Canada than in the United States is discussed.

scholarly journals Barriers to symptom management care pathway implementation in pediatric Cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
L. Lee Dupuis ◽  
Allison Grimes ◽  
Emily Vettese ◽  
Lisa M. Klesges ◽  
Lillian Sung
Keyword(s):  
Clinical Research ◽  
Pediatric Oncology ◽  
Pediatric Cancer ◽  
Symptom Management ◽  
Care Pathway ◽  
The United States ◽  
Care Pathways ◽  
Research Activities ◽  
Pediatric Cancer Patients ◽  
The Impact

Abstract Background Objectives were to describe barriers to pediatric cancer symptom management care pathway implementation and the impact of the COVID-19 pandemic on clinical research evaluating their implementation. Methods We included 25 pediatric oncology hospitals in the United States that supported a grant submission to perform a cluster randomized trial in which the intervention encompassed care pathways for symptom management. A survey was distributed to site principal investigators prior to randomization to measure contextual elements related to care pathway implementation. Questions included the inner setting measures of the Consolidated Framework for Implementation Research (CFIR), study-specific potential barriers and the impact of the COVID-19 pandemic on clinical research. The Wilcoxon rank sum test was used to compare characteristics of institutions that agreed that their department supported the implementation of symptom management care pathways vs. institutions that did not agree. Results Of the 25 sites, one withdrew because of resource constraints and one did not respond, leaving 23 institutions. Among the seven CFIR constructs, the least supported was implementation climate; 57% agreed there was support, 39% agreed there was recognition and 39% agreed there was prioritization for symptom management care pathway implementation at their institution. Most common barriers were lack of person-time to create care pathways and champion their use (35%), lack of interest from physicians (30%) and lack of information technology resources (26%). Most sites reported no negative impact of the COVID-19 pandemic across research activities. Sites with fewer pediatric cancer patients were more likely to agree that staff are supported to implement symptom management care pathways (P = 0.003). Conclusions The most commonly reported barriers to implementation were lack of support, recognition and prioritization. The COVID-19 pandemic may not be a major barrier to clinical research activities in pediatric oncology.

Contract Clinical Research: A Rapidly Changing Marketplace

1996 ◽  
Vol 9 (6) ◽  
pp. 406-415
Author(s):  
Daniel Krichbaum ◽  
Alan Rosenthal
Keyword(s):  
Clinical Research ◽  
The United States ◽  
Considerable Change ◽  
Business Strategies ◽  
Quality Data ◽  
Scientific Integrity ◽  
Research Activities ◽  
Large Numbers ◽  
Research Organizations

Drug development in the United States has undergone considerable change over the past decade. The outsourcing of clinical research activities to Contract Research Organizations (CROs) continues to escalate in an attempt to speed drugs to market faster. The increasing use of business strategies at the investigational site level has fostered the emergence of specialty networks and Site Management Organizations (SMOs). SMOs offer pharmaceutical and biotechnology sponsors the ability to work with a tightly managed network of experienced professional multispecialty research centers that can enroll large numbers of patients and provide high quality data. While these organizations have fundamentally changed the way drugs are developed, they have also contributed to an acceleration of the process and an improvement in the scientific integrity and quality of the data.

scholarly journals Coordinating the research response to COVID-19: Mali’s approach

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Seydou Doumbia ◽  
Ydrissa Sow ◽  
Mahamadou Diakite ◽  
Chuen-Yen Lau
Keyword(s):  
Public Health ◽  
Clinical Research ◽  
Advisory Committee ◽  
Health Research ◽  
Research Capacity ◽  
Open Communication ◽  
Ministry Of Health ◽  
Scientific Advisory Committee ◽  
Research Activities ◽  
Scientific Advisory

Abstract Mali, like the rest of the world, has seen a rapid spread of COVID-19 since the first report of imported cases. Despite being a low-income country, Mali has leveraged scientific research resources via coordinated approaches to enable public health emergency planning and response to the COVID-19 pandemic. Mali’s approach includes the harmonization of research activities; leveraging of research laboratory capacity of the University Clinical Research Center, Mali International Center for Excellence and three other in-country laboratories for community COVID-19 testing; strengthening relationships amongst local and international stakeholders; and collaboration with the Ministry of Health to integrate scientific evidence into public policy and emergency management of COVID-19 through a platform of consultation and open communication. The country has implemented national coordination of its COVID-19 response by establishing a COVID-19 Scientific Advisory Committee and a COVID-19 Technical Coordination Committee, both within the Ministry of Health and working collaboratively with other stakeholders. Members of Mali’s COVID-19 Scientific Advisory Committee also serve as leaders of its principal academic and government clinical and public health research entities. This centralised approach has enabled the prioritisation of COVID-19 control activities, informed allocation of resources, evidence-based public health practices and timely decision-making in the pandemic setting. Though challenges remain, lessons learned from Mali’s harnessing of clinical research capacity to guide and support its COVID-19 response can be applied to future global health research challenges and illustrate the power of building public health-responsive research capacity in resource-limited settings through international collaboration.

scholarly journals A Mobile Gaming Intervention for Persons on Pre-Exposure Prophylaxis: Protocol for Intervention Development and Randomized Controlled Trial (Preprint)

2020 ◽  
Author(s):  
Laura Whiteley ◽  
Elizabeth Olsen ◽  
Leandro Mena ◽  
Kayla Haubrick ◽  
Lacey Craker ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Positive Impact ◽  
Controlled Trial ◽  
The United States ◽  
Developmental Phase ◽  
Randomized Controlled ◽  
Research Activities ◽  
Young Msm ◽  
Exposure Prophylaxis ◽  
Gaming Intervention

BACKGROUND In the United States, young minority men who have sex with men (MSM) are the most likely to become infected with HIV. Pre-exposure prophylaxis (PrEP) is an efficacious and promising prevention strategy. However, PrEP’s safety and effectiveness can be greatly compromised by suboptimal adherence to treatment. To maximize the positive impact of PrEP, it is necessary to combine its prescription with cost-effective behavioral interventions that promote adherence and decrease HIV risk behaviors. In this project, we developed a theoretically informed app/gaming intervention to engage young MSM in learning information, practicing behaviors, and improving motivation for HIV preventative behaviors and PrEP adherence. OBJECTIVE The goal of this project was to develop and test a cutting-edge, engaging, and entertaining app/gaming intervention for improving adherence to PrEP and building HIV prevention knowledge, skills, and behavior. METHODS This study was conducted in two phases. In the developmental phase, we conducted qualitative interviews with young MSM (n=20) to guide the development of the gaming intervention. In the randomized controlled trial, we tested the preliminary efficacy of the gaming intervention compared to a comparison condition among young MSM. Subjects were recruited from the University of Mississippi Medical Center HIV/STI testing clinics (n=60). RESULTS Institutional review board approval was received in February 2015. Research activities began in June 2015 and are still ongoing. CONCLUSIONS This app/gaming intervention aimed to improve PrEP adherence and HIV preventative behaviors in young MSM. Engaging young MSM in learning information, practicing behaviors, and improving motivation for increased adherence to PrEP has the potential to decrease HIV seroconversion. It is important to develop interventions that are enjoyable, engaging, and easily incorporated into clinical settings. CLINICALTRIAL ClinicalTrials.gov RCT02611362; https://tinyurl.com/y65gkuwr INTERNATIONAL REGISTERED REPORT DERR1-10.2196/18640

Neonatology Needs Help

PEDIATRICS ◽  
1992 ◽  
Vol 89 (1) ◽  
pp. 158-158
Author(s):  
Jerold F. Lucey
Keyword(s):  
United States ◽  
Randomized Controlled Trial ◽  
Clinical Research ◽  
Controlled Trial ◽  
The United States ◽  
Bad News ◽  
Good News ◽  
Randomized Controlled ◽  
Number Of Patients ◽  
Prospective Randomized Controlled Trial

I just reviewed the April 1991 issue of Pediatric Research which contains the APS-SPR abstracts. You can't help but notice that neonatology is the most active area of clinical research. Of the 2257 manuscripts submitted, at least 1119 can be classified as neonatal. There are now more than 2500 board-certified neonatologists in the United States. We certainly get high marks for producing abstracts. That's the good news. The bad news, I think, is how trivial, repetitive, and fruitless some of these studies seem to be. I stopped counting when I reached 20 abstracts which ended with the phrase "but of course this study needs to be repeated on a larger number of patients in a prospective randomized controlled trial."

scholarly journals Readiness to Implement Symptom Management Care Pathways in Pediatric Cancer

2020 ◽  
Author(s):  
L Lee Dupuis ◽  
Allison Grimes ◽  
Emily Vettese ◽  
Lisa M. Klesges ◽  
Lillian Sung
Keyword(s):  
Clinical Research ◽  
Pediatric Oncology ◽  
Pediatric Cancer ◽  
Symptom Management ◽  
Care Pathway ◽  
The United States ◽  
Care Pathways ◽  
Research Activities ◽  
Pediatric Cancer Patients ◽  
The Impact

Abstract Background: To describe barriers to pediatric cancer symptom management care pathway implementation and the impact of the COVID-19 pandemic on clinical research evaluating their implementation. Methods: We included 25 pediatric oncology hospitals in the United States that supported a grant submission to perform a cluster randomized trial in which the intervention encompassed care pathways for symptom management. A survey was distributed to site principal investigators to measure contextual elements related to care pathway implementation. Questions included the inner setting measures of the Consolidated Framework for Implementation Research (CFIR), study-specific potential barriers and the impact of the COVID-19 pandemic on clinical research. The Wilcoxon rank sum test was used to compare characteristics of institutions that agreed that their department supported the implementation of symptom management care pathways vs. institutions that did not agree.Results: Of the 25 sites, one withdrew because of resource constraints and one did not respond, leaving 23 institutions. Among the seven CFIR constructs, the least supported was implementation climate; 57% agreed there was support, 39% agreed there was recognition and 39% agreed there was prioritization for symptom management care pathway implementation at their institution. Most common barriers were lack of person-time to create care pathways and champion their use (35%), lack of interest from physicians (30%) and lack of information technology resources (26%). Most sites reported no negative impact of the COVID-19 pandemic across research activities. Sites with fewer pediatric cancer patients were more likely to agree that staff are supported to implement symptom management care pathways (P=0.003). Conclusions: The most commonly reported barriers to implementation were lack of support, recognition and prioritization. The COVID-19 pandemic was not a major barrier to clinical research activities in pediatric oncology.Clinical Trial Registration: NCT04614662

scholarly journals Is the Distribution of Research Grants Sustainable? An Empirical Study of Grant Assessment

2020 ◽  
Vol 12 (17) ◽  
pp. 6891
Author(s):  
Aleksandra Bączkiewicz ◽  
Jakub Dagil ◽  
Bartłomiej Kizielewicz ◽  
Karol Urbaniak ◽  
Wojciech Sałabun
Keyword(s):  
Social Sciences ◽  
Empirical Study ◽  
Basic Research ◽  
Physical Sciences ◽  
Research Grants ◽  
Research Activities ◽  
Scientific Disciplines ◽  
Science Centre ◽  
National Science ◽  
Scientific Fields

Financing of basic research is an important task in supporting research activities and development of dynamically advancing interdisciplinary fields of science. A significant challenge in this aspect is the correct distribution of limited finances sustainably. In this paper, we present an empirical study related to National Science Centre (NSC), which is the main government agency in Poland. NSC funds projects in Arts, Humanities and Social Sciences, Life Sciences and Physical Sciences and Engineering. In this work, we analyse three primary funding schemes of NSC, which are called PRELUDIUM, SONATA and OPUS. Each of theses programms is asigned to another group of scientists from beginners to experts. Projects’ data concerning PRELUDIUM, SONATA and OPUS schemes are collected from NSC projects database (only completed projects) and proccessed for further investigation. Effectiveness and sustainability of projects implemented in scientific fields are analysed concerning criteria such as the total number of book publications, papers, amount of grants and IF points. The results obtained are presented regarding scientific disciplines and panels. Prevailingly, the PRELUDIUM scheme exhibits better results in the majority of criteria and panels.

scholarly journals Impact of COVID-19 on clinical trials and clinical research: A systematic review

2020 ◽  
Vol 10 (3) ◽  
pp. 878-887
Author(s):  
Brijesh Sathian ◽  
Mohammad Asim ◽  
Indrajit Banerjee ◽  
Ana Beatriz Pizarro ◽  
Bedanta Roy ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Clinical Research ◽  
Negative Impact ◽  
The United States ◽  
Sudden Onset ◽  
World Health ◽  
Research Activities ◽  
The World ◽  
The Impact

Background: The World Health Organization has reported more than 31,186,000 confirmed cases of coronavirus disease-19 (COVID-19), including 962,343 deaths, worldwide as on September 21, 2020. The current COVID-19 pandemic is affecting clinical research activities in most parts of the world. The focus on developing  a vaccine for SARS-CoV-2 and the treatment of COVID-19 is, in fact, disrupting many upcoming and/or ongoing clinical trials on other diseases around the globe. On March 18, 2020, the United States Food and Drug Administration (FDA) issued an updated guideline for the conduct of clinical trials during the current health emergency situation. The potential challenges, such as social distancing and quarantines, result in study participants’ inaccessibility and trial personnel for in-person scheduled study visits and/or follow-up. Due to the sudden onset and wide-spread impact of COVID-19, its influence on the management of clinical trials and research necessitates urgent attention. Therefore, our systematic review of the literature aims to assess the impact of the COVID-19 pandemic on the conduction of clinical trials and research. The search for the relevant articles for review included the keywords "COVID-19” AND "clinical trial" in PubMed, MEDLINE, Embase, Google scholar and Google electronic databases. Key findings include: delaying subject enrollment and operational gaps in most ongoing clinical trials, which in turn has a negative impact on trial programmes and data integrity. Globally, most sites conducting clinical trials other than COVID-19 are experiencing a delay in timelines and a complete halt of operations in lieu of this pandemic, thus affecting clinical research outcomes.

scholarly journals Proceedings from the 1st Insights in Hematology Symposium, Cluj-Napoca, Romania March 11-12, 2016

2016 ◽  
Vol 54 (3) ◽  
pp. 157-160
Author(s):  
Anca Bojan ◽  
Ioana Berindan-Neagoe ◽  
S. Ciurea ◽  
Delia Dima ◽  
Shigeo Fuji ◽  
...  
Keyword(s):  
United States ◽  
Clinical Research ◽  
Basic Research ◽  
The United States ◽  
Medical Community ◽  
Editorial Office ◽  
European Research ◽  
Consensus Document ◽  
European Institutions ◽  
The Eu

Abstract In the March 2016 issue of the Lancet Haematology, the editorial office published a paper stating the roadmap for European research in hematology, based on the European Hematology Association (EHA) consensus document that outlines the directions in hematology for the following years across the continent. The meeting entitled “Insights in hematology” is organized a support for the initiative of a roadmap for European hematologists regarding research, may it be basic research or clinical research, but this consensus should not be focused mainly on European institutions, but rather form the backbone of global research between Europe and the United States, Japan or any other country. This will allow Europeans to learn as well as to share their experience with the rest of the scientific and medical community. And the Cluj-Napoca meeting should be followed by other such meetings all across the EU.

Sign in / Sign up

Export Citation Format

Share Document